Number of the records: 1
Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?
- 1.
SYSNO ASEP 0505825 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Článek ve WOS Title Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models? Author(s) Funda, David P. (MBU-M) RID, ORCID
Palová-Jelinková, L. (CZ)
Goliáš, Jaroslav (MBU-M) RID
Kroulíková, Zuzana (MBU-M)
Fajstová, Alena (MBU-M) ORCID
Hudcovic, Tomáš (MBU-M) RID, ORCID
Spíšek, R. (CZ)Article number 967 Source Title Frontiers in Immunology. - : Frontiers Media - ISSN 1664-3224
Roč. 10, MAY 14 (2019)Number of pages 14 s. Language eng - English Country CH - Switzerland Keywords type 1 diabetes ; cell therapy ; animal models Subject RIV EE - Microbiology, Virology OECD category Microbiology R&D Projects NV16-27994A GA MZd - Ministry of Health (MZ) Method of publishing Open access Institutional support MBU-M - RVO:61388971 UT WOS 000467844100001 EID SCOPUS 85067271405 DOI 10.3389/fimmu.2019.00967 Annotation Tolerogenic dendritic cells (tolDCs) are explored as a promising standalone or combination therapy in type 1 diabetes (T1D). The therapeutic application of tolDCs, including in human trials, has been tested also in other autoimmune diseases, however, T1D displays some unique features. In addition, unlike in several disease-induced animal models of autoimmune diseases, the prevalent animal model for T1D, the NOD mouse, develops diabetes spontaneously. This review compares evidence of various tolDCs approaches obtained from animal (mainly NOD) models of T1D with a focus on parameters of this cell-based therapy such as protocols of tolDC preparation, antigen-specific vs. unspecific approaches, doses of tolDCs and/or autoantigens, application schemes, application routes, the migration of tolDCs as well as their preventive, early pre-onset intervention or curative effects. This review also discusses perspectives of tolDC therapy and areas of preclinical research that are in need of better clarification in animal models in a quest for effective and optimal tolDC therapies of T1D in humans. Workplace Institute of Microbiology Contact Eliška Spurná, eliska.spurna@biomed.cas.cz, Tel.: 241 062 231 Year of Publishing 2020 Electronic address https://www.frontiersin.org/articles/10.3389/fimmu.2019.00967/full
Number of the records: 1